Arbutus Provides 2025 Corporate and Financial Update
13 janv. 2025 07h30 HE
|
Arbutus Biopharma Corporation
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 ...